论文部分内容阅读
支气管动脉内灌注化学药物治疗肺癌,近几年来在我国发展很快,其优点在于能缓解症状,延长生命,近期疗效显著而且创伤小,操作简单可重复性强。但在介入治疗中对于提高疗效,合理用药,降低药物毒性反应及减少并发症的措施方面报道较少。现将我们二年来对42例(64次)肺癌患者采用支气管动脉内灌注药物(简称 BAI)进行治疗的体会报告如下。以进行分析与探讨。材料与方法42例肺癌周围型27例,中央型15例,其中男30例,女12例,年龄为19～72岁,平均
Bronchial arterial infusion of chemical drugs for the treatment of lung cancer, has developed rapidly in China in recent years, its advantages are to relieve symptoms, prolong life, the recent significant effect and less trauma, simple and reproducible operation. However, few reports have been reported on the efficacy, rational use of drugs, reduction of drug toxicity and reduction of complications in interventional treatment. Now we have reported the experience of 42 patients (64) lung cancer patients treated with intrabronchial arterial infusion drugs (abbreviated as BAI) in the following two years. For analysis and discussion. Materials and Methods 42 cases of peripheral lung cancer in 27 cases, 15 cases in central type, including 30 males and 12 females, aged 19 to 72 years old, average